Search results
CIDP study explores dual-target CAR-T cell therapy for the treatment of relapsed/refractory...
Medical Xpress· 5 days agoThis study was led by Professor Junnian Zheng and Ming Shi from the Cancer Institute of Xuzhou Medical University, together with the team of Professor Guiyun Cui and Wei Zhang from the Affiliated ...
argenx (NASDAQ:ARGX) Shares Gap Up After Analyst Upgrade
ETF DAILY NEWS· 1 day agoStifel Nicolaus currently has a buy rating on the stock. Several other research firms have also issued reports on ARGX. JPMorgan Chase & Co. decreased their target price on argenx from $560.00 ...
Country music star starting rehab after near-death experience, promises new music
The Patriot-News· 3 days agoColt Ford is still kicking. The country music star checked in with fans this week for the first time...
Argenx’s Vyvgart Shot Gains US Approval for Rare Nerve Disorder
Bloomberg· 4 days agoArgenx SE’s Vyvgart Hytrulo shot gained US approval to treat a rare nervous system disorder, a win...
New Treatment Approved for Chronic Inflammatory Demyelinating Polyneuropathy
MedPage Today· 3 days agoThe FDA expanded the indication of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) Friday...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 6 days agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
Immunovant, Inc. (NASDAQ:IMVT) Forecasted to Post FY2027 Earnings of ($1.84) Per Share
ETF DAILY NEWS· 6 days agoImmunovant, Inc. (NASDAQ:IMVT – Free Report) – Zacks Research issued their FY2027 earnings estimates for shares of Immunovant in a research report issued to clients and investors on Monday, ...
Burke: Ask your doctor if dancing drug ads are right for you | HeraldNet.com
Everett Herald· 5 days ago• For our pointy little heads, there’s Botox injections to cure migraines (oops, not “cure” but rather “relieve the suffering,” which their lawyers apparently think an important distinction) ...